Lyell Immunopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lyell Immunopharma, Inc. on September 16, 2025, regarding events occurring on September 15, 2025. The Company is a Delaware corporation with its principal executive offices in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market under the symbol "LYEL".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a senior executive:
- Resignation: Charles Newton has resigned from his positions as Chief Financial Officer and principal financial and accounting officer.
- Effective Date: The resignation is effective October 31, 2025.
- Reason: There were no disagreements between Mr. Newton and the Company.
- Succession: The Company plans to conduct a search for Mr. Newton's replacement.
- Post-Resignation Arrangement: Mr. Newton has entered into a consulting agreement to provide services to the Company from the Resignation Date until April 30, 2026, or until earlier termination by either party.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors beyond the operational impact of the CFO transition. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Confirm the timeline for the appointment of a new Chief Financial Officer.
- Review the terms of the consulting agreement with Charles Newton for potential compensation implications.
- Monitor subsequent filings for any interim financial officer appointments.
- Verify if the transition period impacts the timing of upcoming financial reporting or audit processes.